Telix Pharmaceuticals Ltd (TLX) stock

TLXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as TLPPF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 20, 2026Score 3/30

$9.23−0.13 (-1.39%)

Close on Nov 13, 2026Market cap $3.13BP/E –Yield –

Telix Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Telix Pharmaceuticals's EV/EBITDA was 69.4× on Nov 11, 2026, against 55.4× a year earlier. Over the last 2 years it ranged from 40.1× to 392.0×, with a median of 76.2×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	69.4×	+28.0
2025	Dec 31, 2025	41.3×	−282.3
2024	Dec 31, 2024	323.6×	–

Where these numbers come from

Parsed from the XBRL in Telix Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing